8 recruiting, 6 active not recruiting, 6 completed, 6 terminated. 16 Phase 2, 5 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Recurrent Oropharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Oropharyngeal Squamous Cell Carcinoma trials Research Report on Recurrent Oropharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-26 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer Biospecimen Collection, Computed Tomography, Elimusertib - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 7 | 2022-07-06 | 2026-08-21 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 188 | 2021-04-27 | 2026-10-21 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Efineptakin alfa - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Hyunseok Kang, MD | 4 | 2021-03-12 | 2025-02-14 |
| Oropharynx (OPX) Biomarker Trial Non-Interventional Study - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Recruiting | Mayo Clinic | 560 | 2019-11-15 | 2026-04-22 | |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer BGJ398 - FGFR Gene Amplification, FGFR1 Gene Amplification | Phase 2 | Terminated | University of Chicago | 1 | 2018-06-01 | 2019-04-16 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Cetuximab, Ficlatuzumab - Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | University of Arizona | 78 | 2017-12-05 | 2024-09-04 |
| Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Not applicable | Terminated | Case Comprehensive Cancer Center | 3 | 2015-03-03 | 2019-01-24 |
| Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer Laboratory Biomarker Analysis, Photodynamic Therapy, Porfimer Sodium - Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 3 | 2014-04-01 | 2017-10-11 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer Cetuximab, Laboratory Biomarker Analysis, Lenalidomide - Recurrent Colon Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2011-02-10 | 2020-03-13 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Capecitabine, Vorinostat - Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2010-12-01 | 2017-04-14 |
Showing 20 of 26. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (26) · Mouth Neoplasms (10) · Carcinoma (9) · Laryngeal Neoplasms (9) · Hypopharyngeal Neoplasms (8) · Lymphoid Interstitial Pneumonia (8) · Oropharyngeal Neoplasms (8) · Tongue Neoplasms (7) · Salivary Gland Neoplasms (6) · Nasopharyngeal Carcinoma (4) · Head and Neck Neoplasms (2) · Carcinoma, Squamous Cell (1) · Colonic Neoplasms (1) · Lip Neoplasms (1) · Nasopharyngeal Neoplasms (1)
Neoplasms (26) · Neoplasms by Histologic Type (26) · Neoplasms by Site (26) · Neoplasms, Glandular and Epithelial (26) · Carcinoma, Squamous Cell (25) · Head and Neck Neoplasms (24) · Stomatognathic Diseases (19) · Mouth Diseases (18) · Carcinoma (17) · Otorhinolaryngologic Diseases (12) · Otorhinolaryngologic Neoplasms (12) · Pharyngeal Diseases (12) · Pharyngeal Neoplasms (12) · Laryngeal Diseases (9) · Respiratory Tract Diseases (9)
Magnetic Resonance Spectroscopy (7) · Specimen Handling (7) · pembrolizumab (7) · Carboplatin (5) · 1,2-diaminocyclohexaneplatinum II citrate (4) · Cetuximab (4) · Cisplatin (4) · Platinum (4) · Radiosurgery (3) · Biopsy (2) · Docetaxel (2) · Paclitaxel (2) · Taxes (2) · cemiplimab (2) · (225)Ac-DOTA-c(RGDyK) (1)
National Cancer Institute (NCI) (13) · Emory University (4) · M.D. Anderson Cancer Center (2) · Case Comprehensive Cancer Center (1) · Hyunseok Kang, MD (1) · Marcelo Bonomi (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · University of Arizona (1) · University of Chicago (1)
United States (25) · Canada (2) · China (1) · Puerto Rico (1) · South Africa (1)
Tanguy Seiwert (2) · Yvonne M Mowery (2) · Dan P Zandberg (1) · Dong M. Shin, MD, FACP, FAAAS (1) · Eric Chen (1) · Eric Winquist (1) · Erin M Bertino (1) · George Blumenschein, MD (1) · Greg Wolf (1) · Hassan Arshad (1) · Hyunseok Kang, MD (1) · Jacob S Thomas (1) · James Rocco (1) · Julie E. Bauman, MD, MPH (1)
PMID 31618129, PMID 36977289, PMID 37012550
P30CA138292 (4), N01CM00032 (2), U10CA180820 (2), UM1CA186690 (2), K24DC022077 (1), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA014599 (1), P30CA016056 (1), P30CA016058 (1), P30CA023074 (1), P30CA043703 (1)